EGFR and non-small cell lung carcinoma: Three generations of EGFR tyrosine kinase inhibitors (TKIs) have been used in the treatment of NSCLC patients with activating mutations in the EGFR gene—the first generation is represented by reversible erlotinib and gefitinib [5], the second generation by irreversible afatinib [6], and the third generation by irreversible osimertinib and lazertinib [7].